Denali治療 DNLI 深 滬
已收盤 04-02 16:00:00 美东时间
20.65
+0.970
+4.93%
華盛通- 最 高20.66
- 今 開18.922
- 成交量 162.58万股
- 最 低 18.92
- 昨 收 19.68
- 總市值 32.75亿
- 52周最高 23.77
- 市盈率 靜 --
- 換手率 1.03%
- 52周最低 12.30
- 委 比 -97.53%
- 總股本 1.59亿
- 歷史最高 93.94
- 量 比 0.66
- 振 幅 8.84%
- 歷史最低 10.57
- 每 手 1
- 風險率 2.64%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Denali Therapeutics Secures $200 Million Royalty Funding
Denali Therapeutics ( ($DNLI) ) just unveiled an update. Denali Therapeutics In...
03-31 23:32
美股大行评级 | 大摩、高盛上调Denali Therapeutics目标价；Chewy、沛齐遭多家大行下调目标价
今日重点评级关注：HC Wainwright & Co.：维持Atossa Therapeutics"买入"评级，目标价从7美元升至25美元；Needham：维持Nkarta"买入"评级，目标价从10美元升至11美元
03-27 10:22
Arm Holdings To Rally Over 27%? Here Are 10 Top Analyst Forecasts For Thursday
Wall Street analysts change ratings on top stocks: BNP Paribas cuts Chewy Inc, Bernstein cuts Qualcomm, Wells Fargo raises United Natural Foods.
03-26 21:08
HC Wainwright & Co. Maintains Buy on Denali Therapeutics, Raises Price Target to $42
HC Wainwright & Co. analyst Andrew S. Fein maintains Denali Therapeutics (NASDAQ:DNLI) with a Buy and raises the price target from $32 to $42.
03-26 19:37
FDA Approves Denali Therapeutics' Avlayah To Treat Hunter Syndrome
https://www.fda.gov/news-events/press-announcements/fda-approves-drug-treat-neurologic-manifestations-hunter-syndrome
03-25 23:48
Denali Therapeutics Announces U.S. FDA Approval of AVLAYAH™ (tividenofusp alfa-eknm) for Treatment of Hunter Syndrome (MPS II)
Denali Therapeutics announces FDA accelerated approval of AVLAYAH™ (tividenofusp alfa-eknm), the first FDA-approved biologic designed to cross the blood-brain barrier for Hunter syndrome, a rare genetic disorder. AVLAYAH is an enzyme replacement therapy indicated for pediatric patients with neurologic manifestations of Hunter syndrome. It is the first treatment in nearly 20 years for this condition and the first in a new class of biotherapeutics ...
03-25 15:50
Relmada Therapeutics, Xenon Pharmaceuticals, Dianthus Therapeutics And Other Big Stocks Moving Higher On Monday
US stocks tumble as Dow falls 650 points. Relmada Therapeutics stock rises 40.8% on promising cancer treatment data. Hims & Hers and Xenon Pharma jump over 40%.
03-09 22:05
美股大行评级 | 花旗：维持康菲石油"买入"评级！目标价从125美元升至135美元
今日重点评级关注：HC Wainwright & Co.：维持Helus Pharma"买入"评级，目标价从55美元升至95美元；HC Wainwright & Co.：维持Compass Pathways"买入"评级，目标价从40美元升至70美元
03-03 20:22
BTIG Maintains Buy on Denali Therapeutics, Raises Price Target to $36
BTIG analyst Thomas Shrader maintains Denali Therapeutics (NASDAQ:DNLI) with a Buy and raises the price target from $32 to $36.
03-02 19:59
财报速睇 | Denali治疗 2025财年Q4营收0.00亿美元，同比增长0.0%；归母净利润亏损1.29亿美元，同比亏损扩大12.0%
华盛资讯2月27日讯，Denali治疗公布2025财年Q4业绩，公司Q4营收0.00亿美元，同比增长0.0%，归母净利润亏损1.29亿美元，同比亏损扩大12.0%。
02-27 06:30
